Is olaparib useful for platinum-resistant ovarian cancer?

Studies show that giving olaparib alone after platinum-based chemotherapy shrinks or clears the cancer increases the time women with ovarian, fallopian tube, or peritoneal cancer live without their disease getting worse.

A study involving 295 patients with relapsed cancer found that patients who received olaparib lived an average of 19.1 months without their disease worsening. In another study involving 265 patients with recurrent cancer, those taking olaparib lived an average of 8.4 months without their disease worsening. In a third study involving 391 patients with advanced cancers with BRCA1 or BRCA2 mutations, about 74% of patients who took Lynparza for two years did not have their disease worsen compared with 35% of patients who took placebo.

When used with bevacizumab, olaparib increases the time patients with HRD-positive cancers lived without disease progression after treatment with platinum-based chemotherapy and who had shrunk or cleared their cancers with bevacizumab. In a major study of 806 patients with advanced high-grade ovarian, fallopian tube, or peritoneal cancer, patients who were HRD-positive and took Lynparza for 22 months lived an average of 37.2 months without their disease worsening.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.